Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00599001 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males
A Phase 1 study, sponsored by Dynavax Technologies Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00599001 is a Phase 1 study that has completed, run by Dynavax Technologies Corporation. The registered enrollment target is 26 participants.
The verdict
NCT00599001, a Phase 1 study, has completed, sponsored by Dynavax Technologies Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety, tolerability, and biological activity of SD-101 compared with placebo in healthy male volunteers.
Interventions
- DRUG placebo
- DRUG SD-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00599001
The ClinicalTrials.gov registry entry for NCT00599001 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dynavax Technologies Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00599001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00599001 about?
NCT00599001 is a clinical study titled "Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males". The main purpose of this study is to assess the safety, tolerability, and biological activity of SD-101 compared with placebo in healthy male volunteers.
What is the current status of trial NCT00599001?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2008-01. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00599001?
The interventions under investigation include: placebo (DRUG), SD-101 (DRUG).
Who is sponsoring clinical trial NCT00599001?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.